BOT - Anything but charting, page-10998

I think it's a good thing he's pointed out the insurance side of things.

It has bought some attention to it on here.

The irony is, here we sit at around $700 mill cap, wondering and fighting on the internet about where insurance negotiations are up to on an FDA approved product that will likely be best in class? How funny.

Meanwhile MSB sits a billion dollars above our market cap and could only dream of being in the position we are in.

CU6 sits at 2.5 billion - lol.

What other ASX bio at this level has the potential that BOT has here and is this far in the game?

We are all still so early!